Tectonic Therapeutic posts Q3 2025 results update

Tectonic Therapeutic, Inc. filed a current report to note that it announced financial results for the quarter ended September 30, 2025 and shared a general business update on November 6, 2025.

Rhea-AI Filing Summary

Tectonic Therapeutic, Inc. filed a current report to note that it announced financial results for the quarter ended September 30, 2025 and shared a general business update on November 6, 2025. These details are contained in a press release furnished as an exhibit to the report.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tectonic Therapeutic, Inc. (TECX) report in its latest 8-K?

Tectonic Therapeutic filed an 8-K stating it announced financial results for the quarter ended September 30, 2025 and provided a general business update. Those details are contained in a press release attached as Exhibit 99.1 to the report.

When did Tectonic Therapeutic (TECX) release its September 30, 2025 quarterly results?

Tectonic Therapeutic announced its quarterly financial results and business update on November 6, 2025. The 8-K notes that the full text of this announcement is provided in a press release, which is included as Exhibit 99.1 to the filing.

Where can investors find the detailed Q3 2025 results for Tectonic Therapeutic (TECX)?

Detailed results are available in the press release furnished as Exhibit 99.1 to Tectonic Therapeutic’s 8-K. The filing states that this exhibit contains the financial results for the quarter ended September 30, 2025 and the related general business update.

What exchange is Tectonic Therapeutic (TECX) common stock listed on?

Tectonic Therapeutic’s common stock, with a par value of $0.0001 per share, is listed on The Nasdaq Stock Market LLC. The 8-K identifies the company’s trading symbol as TECX in the securities registration section.

Who signed the November 6, 2025 8-K for Tectonic Therapeutic (TECX)?

The 8-K was signed on behalf of Tectonic Therapeutic by Daniel Lochner, the company’s Chief Financial Officer. The signature block dated November 6, 2025 confirms he executed the report as a duly authorized officer.

What exhibits are included with Tectonic Therapeutic’s November 6, 2025 8-K?

The 8-K includes Exhibit 99.1, a press release dated November 6, 2025 from Tectonic Therapeutic, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document, as listed under the exhibits section.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/06/2025 - 04:15 PM EST Learn about SEC filing dates

0001681087false00016810872025-11-062025-11-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 06, 2025

Tectonic Therapeutic, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-38537	81-0710585
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
490 Arsenal Way Suite 210
Watertown, Massachusetts				02472
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (339) 666-3320

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		TECX		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 6, 2025, Tectonic Therapeutic, Inc. announced its financial results for the quarter ended September 30, 2025 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

99.1	Press Release of Tectonic Therapeutic, Inc. dated November 6, 2025
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Tectonic Therapeutic, Inc.
Date:	November 6, 2025	By:	/s/ Daniel Lochner
			Daniel Lochner Chief Financial Officer